Answer

Caution is strongly advised when taking licorice with anticonvulsants, specifically those metabolized by the CYP3A4 enzyme. This combination may increase the plasma concentration of certain anticonvulsants, potentially leading to toxicity.

Evidence Assessment

Quality Score: 35 (Tier D - Preliminary/Weak Evidence) The evidence for this interaction is based on pharmacological profiling and CYP450 enzyme inhibition data rather than large-scale clinical trials or published case reports. While the biochemical mechanism is plausible, clinical data on the frequency and severity of this interaction in humans is limited.

Clinical Evidence

The primary concern is the interaction between licorice and anticonvulsants that serve as substrates for the cytochrome P450 3A4 (CYP3A4) enzyme, such as carbamazepine. Licorice acts as a moderate inhibitor of CYP3A4. When an enzyme inhibitor is introduced, the metabolism of the drug is slowed, which can lead to an accumulation of the medication in the bloodstream.

In the case of carbamazepine, increased plasma levels can lead to an escalation of dose-dependent adverse effects, including ataxia, dizziness, nausea, and potentially more severe neurotoxicity. Because the therapeutic window for many anticonvulsants is narrow, even a moderate increase in plasma concentration can shift a patient from a therapeutic state to a toxic state.

Practical Guidance

• Populations at Risk: Patients taking CYP3A4-metabolized anticonvulsants (e.g., carbamazepine) are at the highest risk.
• Monitoring: If licorice is consumed, patients should be monitored closely for signs of anticonvulsant toxicity, such as increased sedation, coordination loss, or blurred vision.
• Dose Adjustment: A reduction in the anticonvulsant dose may be necessary if licorice supplementation is maintained, though this must be managed strictly by a prescribing physician.
• Alternatives: Consider alternative supplements that do not inhibit the CYP3A4 pathway.

Safety & Interactions

Contraindication: Caution / Monitor Closely

• Drug Class: Anticonvulsants (specifically CYP3A4 substrates like carbamazepine).
• Mechanism: Inhibition of CYP3A4 enzyme activity, decreasing the clearance of the drug and increasing systemic exposure.
• Clinical Management: Monitor for increased adverse effects of the anticonvulsant. If toxicity occurs, the supplement should be discontinued immediately.
• High-Risk Populations:
  • Elderly: Increased risk due to naturally declining renal and hepatic clearance.
  • Liver Disease: Patients with hepatic impairment may have reduced CYP450 capacity, exacerbating the inhibitory effect of licorice.
  • Hypertension: Licorice (specifically glycyrrhizic acid) can cause sodium retention and potassium loss, which may complicate the management of patients with cardiovascular comorbidities.

Consult a healthcare provider before combining these substances.